Mazdutide Shows Significant Weight Loss in Phase 3 Trial

Key Summary

• Mazdutide, a dual GLP-1 and glucagon receptor agonist, achieved 16.65% mean weight loss in adults with obesity.
• 84.3% of participants lost at least 5% of their body weight after 60 weeks.
• Significant improvements were observed in waist circumference, blood pressure, triglycerides, LDL cholesterol, and non-HDL cholesterol.
• Gastrointestinal adverse events, including vomiting, nausea, and diarrhea, were common but mostly mild to moderate.
• Findings from the Phase 3 GLORY-2 trial support mazdutide as a promising long-term obesity treatment option.

Mazdutide Delivers Significant Weight Loss in Phase 3 Obesity Trial

Obesity treatment continues to gain momentum as new therapies target multiple metabolic pathways. Results from the Phase 3 GLORY-2 trial show that Mazdutide, a dual GLP-1 and glucagon receptor agonist, produced substantial weight loss and cardiometabolic improvements in Chinese adults with obesity. The findings, published in JAMA, highlight the drug’s potential role in long-term obesity management while underscoring the importance of managing gastrointestinal side effects.

How Effective Is Mazdutide for Weight Loss?

The GLORY-2 trial enrolled 461 Chinese adults with a body mass index (BMI) of 30 kg/m² or higher across 27 hospitals between December 2023 and November 2025. Researchers randomized participants to receive either a once-weekly 9 mg dose of mazdutide or placebo, alongside lifestyle interventions that included a reduced-calorie diet and increased physical activity.

After 60 weeks of treatment, participants receiving mazdutide experienced an average body weight reduction of 16.65%, compared with 1.50% in the placebo group. The treatment also demonstrated strong results across clinically relevant weight-loss targets:

• 84.3% achieved at least 5% weight loss
• 69.9% achieved at least 10% weight loss
• 57.3% achieved at least 15% weight loss
• 42.4% achieved at least 20% weight loss

These outcomes reinforce the growing interest in dual-receptor therapies for patients with moderate-to-severe obesity who require meaningful and sustained weight reduction.

What Cardiometabolic Benefits Were Observed?

Beyond weight reduction, mazdutide delivered notable improvements in several cardiometabolic risk factors that are closely linked to obesity-related complications.

Participants treated with mazdutide recorded:

• A 12.82 cm reduction in waist circumference
• A 9.80 mm Hg decrease in systolic blood pressure
• A 21.06% reduction in triglycerides
• A 14.58% decrease in non-HDL cholesterol
• A 6.94% reduction in LDL cholesterol

These findings suggest that mazdutide may offer broader metabolic benefits that extend beyond body weight management, making it particularly relevant for patients at increased cardiovascular risk.

Safety Profile and Clinical Considerations of Mazdutide

What Side Effects Should Clinicians Monitor?

Gastrointestinal events were the most frequently reported adverse effects. More than half of the participants experienced vomiting (53.1%), while nausea (46.9%) and diarrhea (39.4%) were also common. Most events occurred during dose escalation and were classified as mild to moderate.

Researchers reported treatment discontinuation due to adverse events in 2.9% of participants. Additional safety findings included transient increases in heart rate, cases of sinus tachycardia, four instances of acute gallbladder disease, and two cases of papillary thyroid cancer. No cases of acute pancreatitis or treatment-related deaths were reported.

While the results are encouraging, researchers noted several limitations, including the absence of a lower-dose comparison arm and limited representation of patients with type 2 diabetes.

For Latest Updates, Explore All Endocrinology CME Conferences & Online Courses

For healthcare professionals managing obesity, the GLORY-2 findings position mazdutide as a promising therapeutic option capable of delivering substantial weight loss and cardiometabolic improvements. Future studies across broader populations will help determine its role in global obesity treatment strategies.

Source:

JAMA Network